Table 1. Patient Characteristics.
| Characteristic | No. (%) | P value | |
|---|---|---|---|
| Patients with HS | Controls | ||
| No. | 100 | 100 | NA |
| Age, median (IQR) | 34.5 (27.3-47.0) | 33.5 (27.0-48.8) | NS |
| Sex | |||
| Female | 71 (71) | 71 (71) | NS |
| Male | 29 (29) | 29 (29) | |
| Age at onset, median (IQR), y | 18 (15.0-24.8) | NA | NA |
| Family history | 32 (32) | NA | NA |
| BMI, median (IQR) | 28.9 (24.7-33.3) | 23.4 (21.7-26.8) | <.001 |
| Current or former smoker | 69 (69) | 22 (22) | <.001 |
| History | |||
| IBD | 8 (8) | 0 | .007 |
| Rheumatic disease | 4 (4) | 2 (2) | NS |
| Diabetes mellitus | 7 (7) | 0 | .01 |
| Hurley stage | |||
| I | 64 (64) | NA | NA |
| II | 34 (34) | NA | NA |
| III | 2 (2) | NA | NA |
| IHS4 score, median (IQR) | 0 (0-4) | NA | NA |
| Mild | 74 (74) | NA | NA |
| Moderate | 18 (18) | NA | NA |
| Severe | 8 (8) | NA | NA |
| AN count, median (IQR) | 0 (0-1.8) | NA | NA |
| NRS pain score, median (IQR) | 3 (0-3) | NA | NA |
| Current analgesic medication | |||
| Nonopioid medication | 4 (4) | NA | NA |
| Opioids | 1 (1) | NA | NA |
| Central sensitization (part A CSI) | |||
| CSI score | |||
| Median (IQR) | 31 (19.0-44.8) | 25 (16.0-34.0) | .002 |
| Mean (SD) | 33.7 (18.7) | 25.1 (12.0) | .003 |
| CSI score ≥ 40 | 36 (36) | 12 (12) | <.001 |
| CSS diagnoses (part B CSI) | |||
| 0 | 45 (45) | 57 (57) | .046 |
| 1 | 27 (27) | 29 (29) | |
| >1 | 28 (28) | 14 (14) | |
| Depression | 27 (27) | 19 (19) | .24 |
| Dermatologic diagnosis | |||
| Benign lesiona | NA | 40 (40) | NA |
| Skin cancerb | NA | 27 (27) | NA |
| Mild acne vulgaris | NA | 17 (17) | NA |
| Other | NA | 16 (16) | NA |
Abbreviations: AN, abscess and nodule; BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); IBD, inflammatory bowel disease; CSI, Central Sensitization Inventory; CSS, central sensitization syndrome; HS, hidradenitis suppurativa; IHS4, International Hidradenitis Suppurativa Severity Score System; IQR, interquartile range; NA, not applicable; NRS, numeric rating scale; NS, not significant.
a
Including melasma, verrucae, keloid, and naevus naevocellularis.
b
Including basal cell carcinoma and squamous cell carcinoma.